Table 5. Does performance status (PS) affect SC?
| PS 0/1 (N=759) | PS 2 (N=124) | Pa | |
|---|---|---|---|
| Drugs against treatment side effects | 406 (53%) | 72 (58%) | 0.24 |
| A01 Stomatologicals | 8 (1%) | 1 (1%) | |
| A02 Antacids | 141 (19%) | 33 (27%) | |
| A03 Antispasmodics | 99 (13%) | 11 (9%) | |
| A04 Antiemetics | 141 (19%) | 17 (14%) | |
| A06 Laxatives | 73 (10%) | 17 (14%) | |
| A07 Antidiarrhoeals | 20 (3%) | 2 (2%) | |
| B02 Antihaemorrhagics | 27 (4%) | 5 (4%) | |
| B03 Antianaemics | 41 (5%) | 5 (4%) | |
| J01 Antibacterials for systemic use | 68 (9%) | 8 (6%) | |
| J02 Antimycotics for systemic use | 13 (2%) | 2 (2%) | |
| L03AA Colony-stimulating factors | 71 (9%) | 7 (6%) | |
| Drugs against tumour symptoms | 424 (56%) | 77 (62%) | 0.28 |
| A14 Anabolic agents for systemic use | 8 (1%) | 0 | |
| A15 Appetite stimulants | 1 (<1%) | 0 | |
| B01 Antithrombotic agents | 28 (4%) | 0 | |
| H01AA ACTH | 26 (3%) | 7 (6%) | |
| H02 Corticosteroids for systemic use | 230 (30%) | 52 (42%) | |
| L02AB Progestogens | 11 (1%) | 1 (1%) | |
| M01A Nonsteroidal anti-inflammatory drugs | 122 (16%) | 24 (19%) | |
| M05B Drugs affecting mineralisation | 18 (2%) | 4 (3%) | |
| N02A Opioids | 64 (8%) | 13 (10%) | |
| N02B Other analgesics and antipyretics | 97 (13%) | 20 (16%) | |
| N03 Antiepileptics | 4 (1%) | 0 | |
| R03 Antiasthmatics | 61 (8%) | 9 (7%) | |
| R05C Expettorants | 27 (4%) | 5 (4%) | |
| R05D Cough suppressants | 58 (8%) | 14 (11%) | |
| Drugs against concomitant diseases | 116 (15%) | 28 (23%) | 0.10 |
| A10 Antidiabetics | 12 (2%) | 0 | |
| C Cardiovascular system | 80 (11%) | 20 (16%) | |
| G04 Drugs for prostatic hypertrophy | 2 (<1%) | 0 | |
| H03 Drugs for thyroid | 2 (<1%) | 1 (1%) | |
| N05 Psycholeptics | 22 (3%) | 5 (4%) | |
| N06 Psychoanaleptics | 9 (1%) | 2 (2%) | |
| N07C Antivertigo preparations | 2 (<1%) | 0 | |
Patients with PS 0/1 vs patients with PS 2 in all three studies. The table shows the number (percentage) of patients assuming at least one drug of each category during the first 63 days of treatment. Only patients receiving three or more cycles of chemotherapy are considered.
a
Mantel Haenszel test stratified by treatment arm.